The Risk of Immune-Related Thyroid Dysfunction Induced by PD-1/PD-L1 Inhibitors in Cancer Patients: An Updated Systematic Review and Meta-Analysis

BACKGROUND: Thyroid dysfunction is common for cancer patients receiving PD-1/PD-L1 inhibitor therapies. To clarify the incidence risk of thyroid dysfunction would be important for guiding anti-PD-1 and anti-PD-L1 immunotherapy. Therefore, the updated meta-analysis was conducted to evaluate the incid...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Yuan, Li, Ran, Liu, Yan, Li, Meng, Song, Yuxiao, Zheng, Yan, Gao, Aiqin, Wen, Qing, Su, Guohai, Sun, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312489/
https://www.ncbi.nlm.nih.gov/pubmed/34322382
http://dx.doi.org/10.3389/fonc.2021.667650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312489/
https://www.ncbi.nlm.nih.gov/pubmed/34322382
http://dx.doi.org/10.3389/fonc.2021.667650

Ejemplares similares